Empowering the body to cure disease
Unlocking the therapeutic potential of protein stabilisation
Our Approach
Outrun Therapeutics is a preclinical biotech using E3 ligase inhibition to unlock the therapeutic potential of protein stabilisation for the treatment of cancer and other diseases.
Our Platform
Our proprietary platform has generated our lead programme, a small molecule inhibitor targeting an E3 ligase that destabilises a tumour suppressor protein in hard-to-treat solid tumours.
Our Platform
Our proprietary platform has generated our lead programme, a small molecule inhibitor targeting an E3 ligase that destabilises a tumour suppressor protein in hard-to-treat solid tumours.
Our Company
Spun out of founder Prof. Satpal Virdee’s lab at the world-renowned MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee, we are led by a seasoned management team, backed by M Ventures and MP Healthcare Venture Management.
© Outrun Therapeutics
